Rochester,NY 8/22/2009 12:48:13 AM
Boston Scientific Corporation BSX, Re-treating brain aneurysms some good news for Boston Scientific
Boston Scientific Corporation
A study for evaluvating the risks of after endovascular coil embolization bore of re-treating brain aneurysms some good news for Boston Scientific and Johnson & Johnson's Cordis Corp. subsidiary.
The two authours whom received honoraria or grants from the two device makers examined the results in 311 cases in which patients were treated again after having coils implanted in their brains via catheter. The study indicated that the risk of death or permanent major disability was 1.28 percent, or just more than one in 100.
The study was published in Neurosurgery magazine.
Traditional procedures for treating aneurysms, which are bulges or weaknesses in artery walls, involve clipping the base of the bulge to prevent it from bursting. It's an invasive procedure that usually involves opening the patient's skull or brow.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
